Table 1 Summary of HSP inhibitors regulating proliferative signals in cancer
Name | Structure | Target | Hallmarks of cancer | Cancer cell line | Tumor type | Ref |
|---|---|---|---|---|---|---|
C0818 |
| HSP90 | Inhibit proliferation | HepG2 (IC50 = 2.1 μM) Sk-Hep1 (IC50 = 1.9 μM) | Hepatocellular carcinoma | [75] |
Demethoxycμrcumin |
| HSP90 | Inhibit proliferation | RT4 (IC50 = 10.3 μM) | Bladder cancer | [76] |
Pseμdolaric acid A (PAA) |
| HSP90 | Inhibit proliferation | Hela (IC50 = 2.92 ± 0.09 μM) | Human cervical carcinoma | [77] |
Gephyromycin C (GC) |
| HSP90 | Inhibit proliferation | PC3 (IC50 = 1.79 ± 0.28 μM) | Prostate cancer | [78] |
Daμrisoline |
| HSP90 | Inhibit proliferation | A549 (10 μM) Hop62 (10 μM) | Lung cancer | [79] |
Compound 7t |
| HSP90 | Inhibit proliferation | MCF-7 (IC50 = 2.4 ± 0.1 μM), MDA‐MB‐231 (IC50 = 0.8 ± 0.4 μM), HCT116 (IC50 = 4.8 ± 0.5 μM) | Breast cancer Colon cancer | [81] |
Compound 4a |
| HSP90 | Inhibit proliferation | MCF-7 (IC50 = 21.58 ± 0.57 μM), A549 (IC50 = 31.22 ± 0.31 μM) | Breast cancer Lung cancer | [82] |
HM3 |
| HSP90 | Inhibit proliferation | MCF-7 (IC50 = 1.28 ± 0.005 μM) | Breast cancer | [83] |
Compound 57 |
| HSP90 | Inhibit proliferation | MDA-MB-231 (10 μM), 4T1 (10 μM) | Breast cancer | [88] |
Compound 11 |
| HSP90 | Inhibit proliferation | Hep G2 (IC50 = 27.9 ± 0.7 µM), MCF-7 (IC50 = 44.8 ± 3.6 µM) | Liver cancer, Breast cancer | [89] |
PNSA |
| HSP90 | Inhibit proliferation | HCT-116 (0.25 μM) | Colorectal cancer | [90] |
Boro-BZide (3) |
| HSP90 | Inhibit proliferation | MCF-7 (GI50 = 7.63 μM) | Breast cancer | [93] |
6BrCaQ-C10-TPP |
| TRAP1 | Inhibit proliferation | MDA-MB-231 (IC50 = 0.008 μM) | Breast cancer | [94] |
Compound 12 h |
| HSP90α | Inhibit proliferation | NCI-H522 (> 10 μM) | Lung cancer | [95] |
TAS-116 |
| HSP90α/β | Inhibit proliferation | SK-BR-3 (IC50 = 0.33 μM) | Breast cancer | [96] |
Compound 33 |
| HSP110 | Inhibit proliferation | SW48 (10 μM) | Colorectal cancer | [52] |
DDO-5936 |
| HSP90 | Inhibit proliferation | HCT-116 (IC50 = 8.99 ± 1.21 μM) | Colon cancer | [99] |
Compound 18 h |
| HSP90 | Inhibit proliferation | HCT-116 (IC50 = 1.73 μM) | Colon cancer | [100] |
DDO-5994 |
| HSP90 | Inhibit proliferation | HCT-116 (IC50 = 6.34 μM) | Colon cancer | [101] |
Conglobatin A |
| HSP90 | Inhibit proliferation | MDA-MB-231 (IC50 = 32 ± 2 µM) | Breast cancer | [102] |
Elaiophylins |
| HSP90 | Inhibit proliferation | MDA-MB-231 (IC50 = 0.37 μM), MIA PaCa-2 (IC50 = 0.26 μM) | Breast cancer Pancreatic cancer | [103] |
Compound 29 |
| HSP90 | Inhibit proliferation | A549 (IC50 = 0.15 ± 0.03 μM) | Lung cancer | [105] |
(20S) Ginsenoside Rh2 |
| HSP90 | Inhibit proliferation | HepG2 (IC50 = 5.02 μM) | Liver cancer | [106] |
